Announcing the Olink Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.

September 19, 2023 – Drug Discovery – immunoassays, Olink

Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample. Announcing the Olink Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.

19 September 2023 — Uppsala, Sweden — Olink Holding AB today announced the introduction of Olink Target 48 Mouse Cytokine Panel, a validated multiplexed protein panel that offers a detailed view of the murine immune system, enabling in-depth disease modelling, longitudinal studies and translational research.

The Olink Target 48 Mouse Cytokine Panel represents a new standard in immunoassays giving researchers the ability to accurately measure 43 carefully selected immune-related proteins using as little as 1µl of sample volume. Offering multiplexing with unparalleled specificity combined with high sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal studies over multiple timepoints in individual mice. The transparent validation and streamlined workflow maintains the exceptional standards of performance that users have come to expect from Olink.

The addition of a targeted mouse panel with absolute quantification capabilities adds to Olink’s broad portfolio of proteomics solutions. From pre-clinical mouse models to human clinical applications, Olink provides industry-leading solutions encompassing all stages of drug development and disease modelling.

“Olink Target 48 Mouse Cytokine Panel gives scientists the ability to go deeper into preclinical and translational disease research, tackling some of the most important and challenging questions in biology,” said Jon Heimer, CEO of Olink. “The potential this new product brings to the market is exciting. Requiring minimal sample volume, researchers can gain critical insights into the murine immune system over time. Ultimately allowing for more accurate disease modelling and accelerating drug development.”

Olink worked closely with leading researchers to validate the performance of the panel. “We had the privilege of being an early user of the Olink Target 48 Mouse Cytokine panel and were especially impressed with the data produced using our murine samples” said Cuong Nguyen, associate professor at the Department of Infectious Diseases and Immunology, University of Florida, US. “What stood out was the remarkable quality of the data it provided. Through its higher multiplexing design, we extracted meaningful results from a comprehensive range of over 40 immune-related biomarkers, all with remarkably minuscule volumes of sera.  The sensitivity of the assay undoubtedly sets a new standard. Its performance surpasses other platforms available in the market that we have tried.”

The Olink Target 48 Mouse Cytokine Panel was designed to deliver an in-depth view of cytokine signalling and inflammatory pathways for pre-clinical and translational research. It can be utilised across key application areas to deepen current understanding of molecular pathways involved in the disease initiation and progression. Olink Target 48 Mouse Cytokine Panel is fully compatible with the Olink Signature Q100, a high performance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time.

About Olink
Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden. More details are available at the Olink website.

Olink Proteomics AB, Salagatan 16F, SE-753 30 Uppsala, Sweden